![](https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-1029427612.jpg?VersionId=0P3zz6BVZ5XKk7PUKWiFl..GhGnveiju)
Amgen, BMS and Merck have the most exposure as Big Pharma eyes $183B patent cliff: analyst
While patent cliffs are looming for many of biopharma’s top-selling products, the industry has enormous capacity to respond as “conditions for M&A are favorable,” according to a research note from Morgan Stanley. In the July 11 report, the analysts …